The risk of developing anti-HMGCR IMNM is higher following statin exposure, and patients usually have a severe myopathy, without extra-muscular manifestations; the risk of developing cancer is higher in anti-HMGCR and seronegative IMNM (194). The gene discussed is HMGCR; the disease is myopathy.